Dare Bioscience Inc
DARE2.170USD
+0.010+0.46%
Close 12/24, 16:00（ET）Quotes delayed by 15 min
30.23MMarket Cap
LossP/E TTM
More Details of Dare Bioscience Inc Company
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Dare Bioscience Inc Info
Ticker SymbolDARE
Company nameDare Bioscience Inc
IPO dateApr 10, 2014
CEOJohnson (Sabrina Martucci)
Number of employees21
Security typeOrdinary Share
Fiscal year-endApr 10
Address3655 Nobel Dr Ste 260
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92122-1050
Phone18589267655
Websitehttps://www.darebioscience.com/
Ticker SymbolDARE
IPO dateApr 10, 2014
CEOJohnson (Sabrina Martucci)
Company Executives of Dare Bioscience Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Sabrina Martucci Johnson
Ms. Sabrina Martucci Johnson
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
80.17K
--
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
859.00
--
Mr. Gregory W. (Greg) Matz, CPA
Mr. Gregory W. (Greg) Matz, CPA
Independent Director
Independent Director
42.00
--
Dr. Robin J. Steele, J.D.
Dr. Robin J. Steele, J.D.
Independent Director
Independent Director
--
--
Ms. Jessica D. Grossman, M.D.
Ms. Jessica D. Grossman, M.D.
Independent Director
Independent Director
--
--
Dr. Susan L. Kelley, M.D.
Dr. Susan L. Kelley, M.D.
Independent Director
Independent Director
--
--
Ms. Mardee Haring-layton
Ms. Mardee Haring-layton
Chief Accounting Officer
Chief Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Sabrina Martucci Johnson
Ms. Sabrina Martucci Johnson
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
80.17K
--
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
859.00
--
Mr. Gregory W. (Greg) Matz, CPA
Mr. Gregory W. (Greg) Matz, CPA
Independent Director
Independent Director
42.00
--
Dr. Robin J. Steele, J.D.
Dr. Robin J. Steele, J.D.
Independent Director
Independent Director
--
--
Ms. Jessica D. Grossman, M.D.
Ms. Jessica D. Grossman, M.D.
Independent Director
Independent Director
--
--
Dr. Susan L. Kelley, M.D.
Dr. Susan L. Kelley, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Law Custodial Inc
7.76%
The Vanguard Group, Inc.
2.76%
AMH Equity, Ltd.
1.63%
Geode Capital Management, L.L.C.
0.86%
Johnson (Sabrina Martucci)
0.56%
Other
86.42%
Shareholders
Shareholders
Proportion
Law Custodial Inc
7.76%
The Vanguard Group, Inc.
2.76%
AMH Equity, Ltd.
1.63%
Geode Capital Management, L.L.C.
0.86%
Johnson (Sabrina Martucci)
0.56%
Other
86.42%
Shareholder Types
Shareholders
Proportion
Corporation
9.86%
Investment Advisor
3.69%
Hedge Fund
2.04%
Investment Advisor/Hedge Fund
1.20%
Individual Investor
0.97%
Research Firm
0.13%
Other
82.10%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
59
1.01M
6.94%
--
2025Q3
60
1.01M
11.35%
+107.08K
2025Q2
62
909.51K
16.50%
+77.11K
2025Q1
63
832.40K
15.91%
-575.66K
2024Q4
63
782.40K
14.61%
+121.87K
2024Q3
63
660.53K
14.09%
+53.91K
2024Q2
68
606.70K
13.87%
+32.71K
2024Q1
71
573.99K
13.86%
-587.68K
2023Q4
76
555.67K
14.26%
-521.78K
2023Q3
73
1.08M
7.88%
+535.07K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
328.33K
2.44%
--
--
Jun 30, 2025
AMH Equity, Ltd.
193.60K
1.44%
+29.30K
+17.83%
Jun 30, 2025
Geode Capital Management, L.L.C.
95.45K
0.71%
-450.00
-0.47%
Jun 30, 2025
Johnson (Sabrina Martucci)
80.17K
0.59%
+1.00
+0.00%
Apr 17, 2025
Susquehanna International Group, LLP
106.89K
0.79%
+48.72K
+83.77%
Jun 30, 2025
Renaissance Technologies LLC
71.80K
0.53%
+1.20K
+1.70%
Jun 30, 2025
Walters-Hoffert (Lisa)
36.96K
0.27%
--
--
Apr 17, 2025
State Street Investment Management (US)
23.52K
0.17%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
15.01K
0.11%
-6.71K
-30.89%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1
Date
Type
Ratio
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1
Jun 27, 2024
Merger
12→1
FAQs
Who are the top five shareholders of Dare Bioscience Inc?
The top five shareholders of Dare Bioscience Inc are:
The Vanguard Group, Inc. holds 328.33K shares, accounting for 2.44% of the total shares.
AMH Equity, Ltd. holds 193.60K shares, accounting for 1.44% of the total shares.
Geode Capital Management, L.L.C. holds 95.45K shares, accounting for 0.71% of the total shares.
Johnson (Sabrina Martucci) holds 80.17K shares, accounting for 0.59% of the total shares.
Susquehanna International Group, LLP holds 106.89K shares, accounting for 0.79% of the total shares.
The Vanguard Group, Inc. holds 328.33K shares, accounting for 2.44% of the total shares.
AMH Equity, Ltd. holds 193.60K shares, accounting for 1.44% of the total shares.
Geode Capital Management, L.L.C. holds 95.45K shares, accounting for 0.71% of the total shares.
Johnson (Sabrina Martucci) holds 80.17K shares, accounting for 0.59% of the total shares.
Susquehanna International Group, LLP holds 106.89K shares, accounting for 0.79% of the total shares.
What are the top three shareholder types of Dare Bioscience Inc?
The top three shareholder types of Dare Bioscience Inc are:
Law Custodial Inc
The Vanguard Group, Inc.
AMH Equity, Ltd.
Law Custodial Inc
The Vanguard Group, Inc.
AMH Equity, Ltd.
How many institutions hold shares of Dare Bioscience Inc (DARE)?
As of 2025Q4, 59 institutions hold shares of Dare Bioscience Inc, with a combined market value of approximately 1.01M, accounting for 6.94% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.42%.
What is the biggest source of revenue for Dare Bioscience Inc?
In --, the -- business generated the highest revenue for Dare Bioscience Inc, amounting to -- and accounting for --% of total revenue.
